KRAS and colorectal carcinoma: In addition, the cluster miR-99a/let-7c/miR-125b was identified to play an important role in regulating CRC patient response to anti-EGFR targeting therapy, suggesting that miR-99a/let-7c/miR-125b signature could improve the selection of patients with KRAS wild-type CRC as good candidates for anti-EGFR therapy [63].